CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

UCB

Status

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Treatments: Drug: Rozanolixizumab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05014724

CIDP07

Details and patient eligibility

About

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patient who has taken part in the CIDP04 (NCT04051944) study
• Patient who derives continued benefit from treatment
• All required safety information has been reported as per local laws/regulations, reported to Bionical, as appropriate, and documented in the patient's medical records
• Patient is not pregnant

Exclusion Criteria: